Insulin-like growth factor 1 (IGF-1) is an anabolic peptide hormone primarily synthesized in the Liver under Growth hormone (GH) stimulation, mediating most of GH's effects on tissue growth, cell division, and metabolism. It functions as a master regulator of the growth-versus-longevity trade-off, promoting protein synthesis, cell proliferation, and muscle hypertrophy while simultaneously increasing Cancer risk and potentially shortening life expectancy when chronically elevated. IGF-1 exemplifies the evolutionary principle of Antagonistic pleiotropy—beneficial for development and reproduction, but potentially harmful when sustained at high levels post-maturity.
Think of IGF-1 as a construction foreman at a building site with a bullhorn. When Growth hormone from the pituitary (the head office) gives the order, IGF-1 (the foreman) amplifies that signal across the entire construction site. He directs workers (ribosomes) to lay more bricks (protein synthesis), tells the planning department (mTOR) to keep expansion going, and instructs the demolition crew (apoptosis machinery) to take an extended break—nothing gets torn down while growth mode is active. In childhood, this is perfect: you need that aggressive building schedule. But imagine that foreman never retires. In adulthood, especially with constant overfeeding, he keeps pushing for expansion even when the building is already complete. Rooms that should be renovated or removed (damaged cells) are instead told to multiply. This is how chronically high IGF-1 becomes a cancer risk—the construction site never enters maintenance mode. The evolutionary trade-off: rapid growth and muscle repair come at the cost of reduced quality control and accelerated cellular aging. When you implement time-restricted eating or reduce protein intake, you're essentially giving that foreman scheduled breaks, allowing the maintenance crew (autophagy) to finally do their job.
The IGF-1 signaling cascade operates through multiple interconnected pathways:
Production and Regulation:
- Growth hormone binds to GH receptors on Liver hepatocytes → activates JAK2-STAT5 pathway → transcription of IGF-1 gene
- IGF-1 circulates bound to IGF-binding proteins (IGBPs, primarily IGFBP-3) → ~99% bound, 1% free (biologically active)
- Insulin can also stimulate hepatic IGF-1 production (though less potently than GH)
- Negative feedback: elevated IGF-1 inhibits Growth hormone secretion from pituitary somatotrophs
Receptor Binding and Activation:
- IGF-1 binds IGF-1 receptor (a receptor tyrosine kinase with ~60% homology to Insulin receptor)
- Receptor autophosphorylation on tyrosine residues → recruits IRS-1/IRS-2 (insulin receptor substrates)
Downstream Signaling—Two Major Branches:
graph TD
A[IGF-1 binds IGF-1R] --> B[Receptor autophosphorylation]
B --> C[IRS-1/2 recruitment]
C --> D[PI3K-Akt pathway]
C --> E[MAPK pathway]
D --> F[Akt phosphorylation]
F --> G[mTOR activation]
F --> H[FOXO inhibition]
F --> I["GSK3β inhibition"]
G --> J["Protein synthesis ↑"]
G --> K["Autophagy ↓"]
H --> L["Antioxidant genes ↓"]
H --> M["Cell cycle arrest genes ↓"]
I --> N["Glycogen synthesis ↑"]
E --> O[Ras-Raf-MEK-ERK]
O --> P[CREB activation]
O --> Q["Cyclin D1 ↑"]
P --> R[Cell proliferation]
Q --> R
F --> S[BAD phosphorylation]
S --> T[Apoptosis inhibition]
PI3K-Akt Pathway (Metabolic and Survival):
- IRS-1/2 activates PI3K → PIP₂ converted to PIP₃
- PIP₃ recruits PDK1 and Akt to membrane
- Akt phosphorylated at Thr308 (by PDK1) and Ser473 (by mTORC2)
- Active Akt phosphorylates multiple targets:
- mTORC1 activation (via TSC2 inhibition) → S6K and 4E-BP1 phosphorylation → ribosomal protein synthesis, translation initiation
- FOXO transcription factors (FOXO1, FOXO3a) phosphorylated → nuclear export → reduced expression of autophagy genes (LC3, Atg7), antioxidant enzymes (SOD2, catalase), and pro-apoptotic factors (Bim, FasL)
- GSK3β inhibition → glycogen synthase activation → glycogen synthesis
- BAD phosphorylation → BAD sequestered by 14-3-3 proteins → Bcl-2/Bcl-xL free to inhibit apoptosis
MAPK Pathway (Proliferation):
- IRS → GRB2-SOS complex → Ras activation
- Ras-GTP → Raf kinase → MEK1/2 → ERK1/2
- ERK1/2 enters nucleus → phosphorylates CREB, Elk-1, c-Fos → cyclin D1 upregulation
- Cyclin D1-CDK4/6 complex → Rb phosphorylation → E2F release → S-phase entry
Metabolic Effects:
Clinical Thresholds:
- Normal adult IGF-1: 100-300 ng/mL (age-dependent, peaks in puberty)
- Cancer risk increases notably above 200 ng/mL in adults
- Caloric restriction reduces IGF-1 by 20-40%
- protein intake restriction reduces IGF-1 by 25% (independent of calories)
IGF-1 sits at the nexus of the growth-longevity trade-off, making it central to understanding Mismatch Disease, Cancer risk, metabolic syndrome, and aging. In cPNI practice, IGF-1 serves as both a biomarker and therapeutic target.
Evolutionary Context:
The high-IGF-1 phenotype was adaptive in ancestral environments where Intermittent Living patterns naturally cycled between fed and fasted states, and where reproduction benefits outweighed longevity concerns. Modern chronic overnutrition—especially high protein intake combined with sedentary behavior—creates persistently elevated IGF-1, activating mTOR continuously and suppressing autophagy. This violates evolutionary expectations for cyclical nutrient sensing and is implicated in accelerated aging and inflammaging.
Cancer Biology:
Elevated IGF-1 promotes carcinogenesis through multiple mechanisms:
- Enhanced cell proliferation and reduced apoptosis in premalignant cells
- Breast Cancer: IGF-1 >200 ng/mL associated with 28% increased risk; IGF-1 promotes estrogen receptor signaling
- Prostate cancer: IGF-1 >185 ng/mL associated with 2.5-fold increased risk
- Colon cancer: IGF-1 promotes colonocyte proliferation; high animal protein intake increases risk via IGF-1 pathway
- Anti-apoptotic effects allow damaged cells to escape quality control
- IGF-1 promotes angiogenesis via VEGF upregulation
Musculoskeletal System:
Metabolic Integration:
Intervention Strategies:
- Time-restricted eating (16:8 protocol): reduces IGF-1 by 15-25%, activates autophagy during fasting window
- Protein cycling: alternate high-protein days (1.6 g/kg) with moderate-protein days (0.8 g/kg) → prevents chronic IGF-1 elevation while preserving muscle mass
- Plant-based protein bias: vegetal proteins raise IGF-1 less than animal proteins due to lower Leucine density and presence of IGF-1-suppressing phytochemicals
- Exercise periodization: use Exercise to transiently spike IGF-1 for anabolism, follow with recovery periods and lower protein intake
- Fasting-mimicking diets: 5-day protocols every 1-3 months reduce IGF-1 by 40-70%, promote stem cell regeneration
Patient Populations:
- Cancer survivors: monitor IGF-1; target <150 ng/mL through dietary modification
- Metabolic syndrome patients: elevated IGF-1 often co-occurs with hyperinsulinaemia; address via Intermittent fasting
- Athletes: strategically elevate IGF-1 post-training for recovery; implement off-season protein restriction
- Aging populations: gradual IGF-1 decline contributes to sarcopenia, but exogenous supplementation increases cancer risk—resolve via Intermittent Living with strategic protein pulses
- Autoimmune conditions: high IGF-1 may exacerbate Autoimmunity via reduced Treg cells function (FOXO inhibition impairs Treg development)
Exam-Relevant Integration:
IGF-1 exemplifies how the 5 plus 2 metamodel operates: it connects metabolic-system (nutrient sensing), immune (proliferation control), neuro (via BDNF interactions), endocrine (GH axis), and musculoskeletal (anabolism). The Selfish immune system model applies: elevated IGF-1 diverts resources toward proliferation at expense of immune surveillance quality. The Evolutionary trade-offs principle is embodied: growth versus longevity, reproduction versus maintenance.
- IGF-1 production increases 2-3 fold during puberty (GH pulse amplitude peaks), then declines ~1% per year after age 30
- ~98-99% of circulating IGF-1 is bound to IGFBPs (primarily IGFBP-3), with only 1-2% free and biologically active
- protein intake above 1.2 g/kg/day increases IGF-1 by approximately 10 ng/mL per 0.2 g/kg increment
- Caloric restriction of 30-40% reduces IGF-1 by 25-40% in humans within 3-6 months, independent of protein intake
- IGF-1 >200 ng/mL in adults associated with 28% increased breast cancer risk and 40% increased prostate cancer risk
- time-restricted eating (16:8 daily) reduces IGF-1 by 15-20% without caloric restriction
- IGF-1 activates mTORC1 via Akt-mediated inhibition of TSC2, suppressing autophagy within 30-60 minutes
- Resistance exercise transiently increases IGF-1 by 20-40% for 30-90 minutes post-workout, then returns to baseline
- IGF-1 half-life is 12-15 hours (longer than Insulin due to IGFBP binding)
- FOXO transcription factors are inhibited by IGF-1-Akt signaling, reducing expression of 200+ longevity-associated genes
- Dwarf mice with IGF-1 receptor mutations live 30-40% longer than wild-type; similar effects seen in C. elegans and Drosophila
- IGF-1 inhibits apoptosis by phosphorylating BAD at Ser136, preventing Bax/Bak-mediated cytochrome c release
- Vegan diets reduce IGF-1 by 9-13% compared to omnivorous diets, independent of total protein intake
- IGF-1 receptor — primary receptor tyrosine kinase through which IGF-1 exerts all biological effects; 60% homologous to insulin receptor
- Growth hormone — hypothalamic-pituitary hormone that stimulates hepatic IGF-1 synthesis via JAK2-STAT5 pathway; IGF-1 mediates most systemic GH effects
- mTOR — central nutrient sensor activated by IGF-1 via Akt-TSC2 pathway; drives protein synthesis and inhibits autophagy
- AKT pathway — primary signaling cascade downstream of IGF-1 receptor, integrating metabolic, proliferative, and survival signals
- FOXO — transcription factors that promote longevity genes, antioxidant defenses, and autophagy; inhibited by IGF-1-Akt phosphorylation
- Breast Cancer — IGF-1 >200 ng/mL increases risk by 28%; promotes estrogen receptor signaling and anti-apoptotic pathways
- prostate cancer — strongly associated with elevated IGF-1; levels >185 ng/mL confer 2.5-fold increased risk
- Colon cancer — IGF-1 promotes colonocyte proliferation; high animal protein diets increase risk via IGF-1-mTOR axis
- Intermittent fasting — reduces IGF-1 by 15-25% and activates FOXO-dependent longevity pathways
- time-restricted eating — 16:8 protocol lowers IGF-1 independent of caloric restriction, improving metabolic flexibility
- Caloric restriction — reduces IGF-1 by 25-40% in humans; primary mechanism for lifespan extension in model organisms
- protein intake — directly regulates IGF-1 synthesis; intake >1.2 g/kg/day progressively increases levels
- Leucine — branched-chain amino acid that potently stimulates IGF-1 secretion and mTORC1 activation
- muscle hypertrophy — IGF-1 promotes via satellite cell proliferation, protein synthesis, and mTOR activation
- Satellite cells — muscle stem cells activated by IGF-1 for repair and hypertrophy post-exercise
- Insulin — structurally similar to IGF-1 (50% sequence homology); shares receptor cross-reactivity and metabolic effects
- Insulin resistance — often co-occurs with elevated IGF-1 in states of chronic nutrient excess and visceral adiposity
- autophagy — suppressed by IGF-1-mTOR signaling; chronic elevation impairs cellular quality control
- BDNF — brain-derived neurotrophic factor; shares downstream signaling overlap with IGF-1 in neuronal survival and plasticity
- Cancer — elevated IGF-1 promotes tumor initiation and progression via enhanced proliferation and reduced apoptosis
- life expectancy — inversely correlated with IGF-1 levels in model organisms; lower IGF-1 associated with extended healthspan
- sarcopenia — age-related IGF-1 decline contributes to muscle loss, yet chronic elevation accelerates cellular aging
- aging — IGF-1 exemplifies antagonistic pleiotropy—beneficial early in life but promotes aging when chronically elevated
- Metabolic flexibility — impaired by constitutive IGF-1-mTOR activation; restored by fasting and protein cycling
- Glucose — IGF-1 enhances muscle glucose uptake via GLUT4 translocation, mimicking insulin action
- Liver — primary site of IGF-1 synthesis in response to growth hormone stimulation
- Osteoblasts — express IGF-1 receptors; IGF-1 promotes bone formation and calcium incorporation
- Collagen synthesis — enhanced by IGF-1 in fibroblasts, osteoblasts, and chondrocytes
- Exercise — transiently increases IGF-1 for anabolic signaling; timing and protein co-administration optimize muscle adaptation
- Antagonistic pleiotropy — IGF-1 exemplifies this evolutionary principle: promotes growth and reproduction early in life but accelerates aging later
- Module 2 — Growth hormone-IGF-1 axis in endocrine system regulation
- Module 7 — Metabolic integration, nutrient sensing, and cancer biology
- Module 10 — Musculoskeletal anabolism, bone metabolism, and exercise physiology